In a new op-ed for the Globe and Mail, Conscience’s Chief Policy and Partnerships Officer, Richard Gold, examines a critical gap in Ottawa’s Pharmaceutical and Life Sciences Sector Task Force report. While the Task Force’s 39 recommendations focus on easing regulation and pharmaceutical pricing protections, the piece argues they overlook the pipeline needed to move Canadian research out of universities and into companies capable of developing it into new medicines. Drawing on Canada’s own track record — including the open science partnerships that gave rise to Conscience itself — Richard makes the case that sustained investment in these models is essential to building a stronger, more self-sufficient Canadian life sciences industry.
